[…] novel therapies targeting muscle and cardiac tissue. Among the disease KateTx plans to tackle are FSHD and myotonic dystrophy Type 1. Efforts to deliver gene therapies into cells typically rely […]
Kate Therapeutics is pursuing FSHD treatment
Orphan drug designation for Epic Bio’s FSHD candidate
[…] has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy ( FSHD), the most common form of muscular dystrophy in adults. EPI-321 is an investigational therapy […]
Our latest publication from FSH Society’s Living with FSHD Series is now available!
Our latest publication from FSH Society’s Living with FSHD Series is now available! For details HERE. To read the “FSHD: A Guide for Schools” on-line PDF
FSH Society grantees publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy”
[…] publish new paper “RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy” in The American Society of Gene & Cell Therapy providing proof-of-principle for RNAi therapy […]
Past FSH Society fellows publish research paper “Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD”
[…] research paper “Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD” in Epigenetics that proposes a prognostic marker that can be measured in a relatively […]